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Purpose: To review the current status of hypoxia PET 
imaging for delineating hypoxic volumes (HVs) inside the 
gross target volume (GTV) and for radiotherapy (RT) outcome 
prediction. 
Methods: Hypoxia PET tracers currently used in clinical trials 
are mainly [18F]-FMISO, [18F]-FAZA and [18F]-HX4. Different 
image acquisition protocols and methods for delineating HVs 
will be presented in this talk. Furthermore, results of recent 
clinical trials will be reviewed where the prognostic value of 
hypoxia PET imaging before and during RT with respect to 
outcome as investigated. 
In our institution, a clinical phase II trial is currently carried 
out where to date n=33 head and neck cancer patients were 
included. Patients were examined using dynamic FMISO PET 
imaging plus conventional FDG PET imaging in addition to 
planning CT and eventually MRI before the start of RT. HVs 
were segmented based on parameters derived from the 
pharmaco-kinetic analysis of the dynamic FMISO PET data. 
Patients were randomized into two treatment arms. Patients 
in the experimental arm were treated with a 10% dose 
escalation to the HV whereas patients in the control arm 
received standard IMRT treatment with 70 Gy in 35 fractions.  
Results: Different manual and (semi-)automatic methods for 
HV delineation based on hypoxia PET data have been used in 
clinical studies, such as thresholding, tumour-to-background 
ratio (TBR) based methods, advanced automatic methods or 
delineations based on dynamic PET imaging. Different 
contouring techniques for HV definition may result in strongly 
varying volumes. Recently published clinical trials confirm 
the prognostic character of hypoxia PET imaging. However, 
no consensus was found yet with regard to the timing of the 
hypoxia PET examination. Some studies found that pre-
treatment hypoxia PET information was correlated to 
outcome whereas others stated that hypoxia PET data 
acquired two weeks into RT had prognostic value. 
For our hypoxia dose painting trial, a planned interim analysis 
was carried out after recruiting n=20 patients. Median follow-
up time for this group was 36 (11 - 52) months. 5 patients did 
not show any tumour hypoxia (HV = 0 mL). The mean HV of 
the hypoxic tumours was 8.6 mL (0.3 – 49.2 mL). 
Furthermore, data acquired in this study could confirm a 
prognostic model relating TCP to a measure derived from 
dynamic FMISO PET imaging acquired before the start of RT. 
Conclusion: Hypoxia PET imaging is a very promising tool for 
the stratification of patients into different risk groups and 
thus a potentially very interesting molecular marker in the 
advent of biologically adapted, personalized RT. However, a 
comparison of results from different clinical trials is difficult 
due to large discrepancies in terms of imaging protocols and 
data analysis strategies. 
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Pre-RT MR spectroscopic imaging ( MRSI) has been described 
as a promising non invasive tool to depict GBM behaviour and 
extension. 
We confirmed this based on data from an in-house 
prospective clinical trial for GBM, analysing both pre and 
relapse MRSI and published the predctive value of Cho/NAA>2 
( CNR2) regions for the site of relapse .  We then elaborated 
a dose-painting clinical trial aiming to increase dose to CNR2 
regions on biopsied or resected glioblastoma. 
First, as MR spectroscopy metabolic maps are not delivered in 
a DICOM format, we developed an automated image 
processing tool for MR  spectroscopy data integration onto 
planning CT. 
Then we performed a dosimetric study for each patient, 
comparing doses to organs at risk with three different 
treatments : 1) with conventional 3D RT at 60 Gy / 2 Gy 
fractions targeted to contrast enhancement, CE + 2cm ) same 
treatment with an addition SIB IMRT, Simultaneous Integrated 
Boost with Intensity Modulated RadioTherapy ( i.e. 2.4 Gy by 
fraction on the boost), the boost being the MR spectroscopy 
abnormalities ( Cho/NAA ratio>2 + 1cm)  3) SIB IMRT targeted 
to MR Spectroscopy abnormalities + contrast enhancement + 
3mm . Then the V10 Gy and V40 Gy to normal brain and V54 
to brainstem were compared. The dosimetric comparaison 
showed that the doses to organs at risk were lower with 
increased dose SIB IMRT 72 Gy than with standard 60 Gy 
conventional RT and equivalent to 60 Gy IMRT.  The size of 
the SIB could be increased to spectral abnormalities + 
contrast enhancement without increasing dose to organs at 
risk. 
Finally,  we started in 2011 a prospective  phase III 
randomized clinical trial SPECTRO GLIO, financed by the 
French national Cancer Institute ( INCa). The goal is the 
inclusion of 220 patients treated in 9 french centers.  
Standard treatment delivers 60 GY+ Temozolomide, targeted 
to CE+2cm;  patients included in the experimental arm 
receive an additional 72Gy SIB targeted to MRSI 
abnormalities+1cm and to Contrast enhancement. The 
endpoint is survival. 
This ongoing trial includes a centralized MR spectroscopy 
post-treatment  and CHO/NAA>2 maps integration to planning 
CT . Target volumes and Organs at risk delineation are also 
centralized at our institution for all participating centers.  
An external online quality control of the dosimetry is 
performed for each patient included in the experimental 
arm. 
Patients undergo MRI and MRSI before and every two months 
after RT, as well as MR perfusion and diffusion.  
We  recently published a preliminary study of Lactate on 
MRSI, as lactate is a surrogate of tumor hypoxia and 
radioresistance.  We defined a lactate/NAA>0.4  threshold , 
having a  predictive value for the site of relapse. This data 
will have to be confirmed on the larger set of data from the 
Spectro GLio trial as well as MR diffusion and perfusion that 
are performed longitudinally in this trial.  
Conclusion: In our talk we will describe the different steps of 
a dose-painting clinical trial based on metabolic imaging with 
MRSI in GBM: 
-        study of  the predictive value for the site of relapse of 
GBM  
-        developping a quantification and integration method of 
the metabolic maps into planning CT 
